NATCO PHARMA Financial Statement Analysis
|
||
|
The Revenues of NATCO PHARMA have increased by 47.72% YoY .
The Earnings Per Share (EPS) of NATCO PHARMA has increased by 97.91 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NATCO PHARMA Last 5 Annual Financial Results
[BOM: 524816|NSE : NATCOPHARM]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr | ₹1,915 Cr |
| Expenses | ₹2,247 Cr | ₹1,795 Cr | ₹1,681 Cr | ₹1,448 Cr | ₹1,332 Cr |
| Operating Profit (Excl OI) | ₹1,751 Cr | ₹912 Cr | ₹264 Cr | ₹604 Cr | ₹583 Cr |
| Other Income | ₹128 Cr | ₹129 Cr | ₹99 Cr | ₹106 Cr | ₹107 Cr |
| Interest | ₹19 Cr | ₹15 Cr | ₹18 Cr | ₹13 Cr | ₹22 Cr |
| Depreciation | ₹187 Cr | ₹164 Cr | ₹143 Cr | ₹117 Cr | ₹100 Cr |
| Profit Before Tax | ₹1,674 Cr | ₹862 Cr | ₹202 Cr | ₹580 Cr | ₹569 Cr |
| Profit After Tax | ₹1,388 Cr | ₹715 Cr | ₹170 Cr | ₹442 Cr | ₹458 Cr |
| Consolidated Net Profit | ₹1,388 Cr | ₹715 Cr | ₹170 Cr | ₹441 Cr | ₹461 Cr |
| Earnings Per Share (Rs) | ₹77.56 | ₹39.19 | ₹9.32 | ₹24.16 | ₹25.32 |
| PAT Margin (%) | 32.05 | 24.83 | 7.67 | 21.23 | 22.26 |
| ROE(%) | 25.88 | 15.66 | 4.06 | 11.27 | 12.71 |
| ROCE(%) | 30.08 | 18.06 | 4.86 | 13.99 | 14.82 |
| Total Debt/Equity(x) | 0.06 | 0.03 | 0.09 | 0.06 | 0.08 |
Key Financials |
||
| Market Cap | : | ₹ 25,409.8 Cr |
| Revenue (TTM) | : | ₹ 4,560.6 Cr |
| Net Profit(TTM) | : | ₹ 1,944.0 Cr |
| EPS (TTM) | : | ₹ 108.5 |
| P/E (TTM) | : | 13.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | -0.3% | 3.2% | 90% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 1.7% | 45.7% |
| CIPLA | 1.7% | 0.5% | 23.7% |
| DR REDDYS LABORATORIES | 5.7% | 12.4% | 18.5% |
| ZYDUS LIFESCIENCES | -1.4% | 3.1% | 44.8% |
| DIVIS LABORATORIES | -0.1% | -2.2% | 56.9% |
| MANKIND PHARMA | 4.2% | 9.8% | 49.8% |
| TORRENT PHARMACEUTICALS | 2.2% | 10.6% | 61.7% |
| LUPIN | 4.1% | 5.1% | 71.7% |
NATCO PHARMA Revenues
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 47.72 % |
| 5 Yr CAGR | 20.21 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | 7.16 | |
| Mar2020 | ₹1,915 Cr | - | |
NATCO PHARMA Operating Profit
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 92.10 % |
| 5 Yr CAGR | 31.68 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,751 Cr | 92.10 | |
| Mar2023 | ₹912 Cr | 246.00 | |
| Mar2022 | ₹264 Cr | -56.36 | |
| Mar2021 | ₹604 Cr | 3.64 | |
| Mar2020 | ₹583 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 30.05 % |
| 5 Yr CAGR | 9.54 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 43.8% | 30.05 | |
| Mar2023 | 33.68% | 148.56 | |
| Mar2022 | 13.55% | -53.94 | |
| Mar2021 | 29.42% | -3.29 | |
| Mar2020 | 30.42% | - | |
NATCO PHARMA Profit After Tax
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 94.09 % |
| 5 Yr CAGR | 31.75 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,388 Cr | 94.09 | |
| Mar2023 | ₹715 Cr | 320.76 | |
| Mar2022 | ₹170 Cr | -61.44 | |
| Mar2021 | ₹441 Cr | -4.32 | |
| Mar2020 | ₹461 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 29.08 % |
| 5 Yr CAGR | 9.54 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 32.05 % | 29.08 | |
| Mar2023 | 24.83 % | 223.73 | |
| Mar2022 | 7.67 % | -63.87 | |
| Mar2021 | 21.23 % | -4.63 | |
| Mar2020 | 22.26 % | - | |
NATCO PHARMA Earnings Per Share (EPS)
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 97.91 % |
| 5 Yr CAGR | 32.30 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹78 | 97.91 | |
| Mar2023 | ₹39 | 320.49 | |
| Mar2022 | ₹9.32 | -61.42 | |
| Mar2021 | ₹24 | -4.58 | |
| Mar2020 | ₹25 | - | |
NATCO PHARMA Return on Capital Employed (ROCE)
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 66.56 % |
| 5 Yr CAGR | 19.36 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 30.08% | 66.56 | |
| Mar2023 | 18.06% | 271.60 | |
| Mar2022 | 4.86% | -65.26 | |
| Mar2021 | 13.99% | -5.60 | |
| Mar2020 | 14.82% | - | |
NATCO PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,418.8 |
| Current MarketCap | : | ₹ 25,409.8 Cr |
| Updated EOD on | : | Dec 20,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -0.3% |
3.2% |
90% |
| SENSEX | -5% |
0.6% |
9.2% |
NATCO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 0.1% | 4% | 45% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE SMALL CAP | -3.2% | 5.1% | 31.1% |
| S&P BSE MIDSMALLCAP | -3.2% | 4.4% | 29.5% |
| S&P BSE 400 MIDSMALLCAP | -3.5% | 3.6% | 26.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 1.6% | 3.4% | 39.1% |
| NIFTY SMALLCAP250 | -3.1% | 5% | 28% |
| NIFTY MID SMALL400 | -3.2% | 4.3% | 26% |
| NIFTY FREE SMALL 100 | -3.6% | 5.9% | 25.7% |
| NIFTY500 MULTICAP 50:25:25 | -4.1% | 2.4% | 19.8% |
You may also like the below Video Courses
FAQ about NATCO PHARMA Financials
How the annual revenues of NATCO PHARMA have changed ?
The Revenues of NATCO PHARMA have increased by 47.72% YoY .
How the Earnings per Share (EPS) of NATCO PHARMA have changed?
The Earnings Per Share (EPS) of NATCO PHARMA has increased by 97.91 % YoY .
Check out Intrinsic Value of Peers of NATCO PHARMA
Compare Stock Analytics of Peers of NATCO PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
